Events (ILLUMINATE) trial, torcetrapib, which increased HDL-C in the range of 60% to 100% and lowered LDL-C by up to 20%, actually increased CVD events, 7 a result likely associated with off-target effects on blood pressure and adrenal synthesis of mineralo-and glucocorticoids. 8 In the Effects of Dalcetrapib on Cardiovascular Risk Among Patients With a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial, dalcetrapib, which did not have off-target effects and raised HDL-C ≈30%, there was no effect on CVD. 9 More recently, in A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE), a CVD outcome study with evacetrapib, 10 another CETP inhibitor without off-target effects, was stopped early because of apparent insufficient efficacy of the drug although no specific data have been presented yet. Two additional CETP inhibitors under development, anacetrapib (ANA) and TA-8995, do not seem to have the off target effects of torcetrapib and increase HDL-C by up to 140% to 180%. 11, 12 The Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) study determining the effect of ANA on CVD outcomes is ongoing, whereas TA-8995 is at an earlier stage of development. 13, 14 As a result, the controversy regarding the effect of pharmacological inhibition of CETP on reverse cholesterol transport continues. 15 A previous study of the CETP inhibitor torcetrapib, administered as monotherapy, significantly increased plasma concentrations of apoA-I and apoA-II by reducing their fractional clearance rates (FCR) from plasma. 16, 17 However, there was no discernable effect of torcetrapib on apoA-I FCR when it was added to atorvastatin (ATV) although power was limited. 16 In this study, we determined the effects of ANA on the metabolism of HDL apoA-I and apoA-II with or without ATV therapy. Inhibition of CETP activity also increases plasma levels of CETP although the mechanism responsible for this increase is unknown. 18 We report, for the first time, the effects of a CETP inhibitor on the metabolism of CETP.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Thirty-nine participants completed this study. Ten were in placebo (PBO)-ANA, and 29 were in ATV-ANA. There were 4 (40%) and 9 (31%) females in PBO-ANA and ATV-ANA, respectively. Mean age was 50.6±11.3 years in the PBO-ANA group and 46.7±10.4 in the ATV-ANA group. Body mass index ranged from 20.5 to 37.7 kg/m 2 across the 2 groups. Screening lipid levels were similar in both groups (Table 1 ). There were no significant differences in baseline demographic parameters between the ATV-ANA and PBO-ANA groups.
Effects of ANA on lipids and lipoproteins are presented in Table 2 . At the end of the statin or PBO run-in period, plasma lipid levels differed between ATV-ANA and PBO-ANA because of the administration of ATV, 20 mg/d, in the ATV-ANA group. In the ATV-ANA group, 8 weeks of ANA treatment on a statin background resulted in an increase in HDL-C (68.1%; P<0.001), and a decrease in LDL-C (38.0%; P<0.001), with no changes in triglycerides. In the PBO-ANA group, HDL-C increased (53.5%; P=0.055) and LDL-C decreased (34.5%; P=0.039). Triglyceride levels also decreased in PBO-ANA (24.5%; P=0.012). Plasma apoA-I concentrations increased in the ATV-ANA (29.3%) and PBO-ANA (29.7%) groups after ANA treatment (P<0.001 for both the ATV-ANA and PBO-ANA groups). Plasma apoA-II levels also increased in both the ATV-ANA (11.9%; P<0.001) and the PBO-ANA (13.3%; P=0.008) groups.
We isolated HDL by ultracentrifugation to determine the effects of ANA treatment on lipid composition. 19 The cholesterol content in isolated HDL increased by 85.2% in the ATV-ANA group (P<0.001) and by 97.8% in the PBO-ANA group (P<0.001); CE, which accounted for >80% of the total cholesterol content in the HDL fractions, increased by 81.0% in the ATV-ANA group (P<0.001) and by 89.8% in the PBO-ANA group (P<0.001). HDL-triglyceride content decreased by 53.7% in the ATV-ANA group (P<0.001) and by 46.6% in the PBO-ANA group (P<0.001). The cholesterol esterification rate was decreased in both groups (ATV-ANA by 32.0%, P<0.001, and PBO-ANA by 34.9%, P<0.001).
The metabolism of HDL apoA-I and apoA-II was examined at the end of the 4 week run-in period with PBO or statin and after addition of ANA for 8 weeks ( Figure 1 and Table 3 ). The increase in apoA-I pool size during ANA treatment was because of a significant decrease in the HDL apoA-I FCR (15.7% in the ATV-ANA and 20.7% in the PBO-ANA group; P=0.009 and P=0.029, respectively). There were no significant changes in the production rate (PR) of apoA-I in either group. Despite small but significant increases in plasma apoA-II levels in each group, we did not observe significant changes in either FCRs or PRs of apoA-II.
We determined the distribution of HDL subpopulations by 2-dimensional gel electrophoresis. 20, 21 In both groups, there were marked increases in both the proportion and absolute amount of apoA-I in α-1 HDL ( Table 4 and Table I in the online-only Data Supplement). Absolute concentrations of apoA-I in pre-β-1 particles increased proportionately at the end of ANA treatment in both groups, without any changes in the percent of apoA-I in pre-β-1 HDL particles. There were parallel increases in both the absolute amount and proportion of apoA-II in α-1 HDL particles (Tables II  and III were, in general, reductions in the proportion of apoA-I and apoA-II in the smaller, α-2, α-3, and α-4 HDL subfractions in both groups. CETP mass increased 108% in the ATV-ANA group (P<0.001) and 91.2% in the PBO-ANA group (P=0.002; Table 5 ). This increase was caused by a significant reduction in the FCR of CETP (59.2% in the ATV-ANA group and 53.6% in PBO-ANA group; P<0.001 and P=0.002, respectively), with no change in CETP PR in either group ( Figure 2 and Table 5 ). We did not find a correlation between changes in CETP mass and changes in HDL cholesterol levels. The impact of the change in CETP FCR on CETP mass is evident from the relatively strong correlation observed between changes in FCR and changes in CETP mass from period 1 to period 2 (r=0.66; P<0.0001). The FCRs for CETP at the end of period 1 were 0.44 and 0.48 pools/d for the ATV-ANA and PBO-ANA groups, respectively. These FCRs are similar to the FCR for LDL apoB (0.44 pools/d) in these same ATV indicates atorvastatin; ANA, anacetrapib; CI, confidence interval; HDL-c, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, high-density lipoprotein cholesterol; and PBO, placebo.
*P values are for null hypothesis that there is no difference between the 2 population means for ATV-ANA and PBO-ANA. For the continuous variables (age, body weight, body mass index, and lipid values), P values are from equal variance 2 sample 2-tailed t test. For sex, P value is from χ 2 test for proportion.
participants during statin or PBO treatment. 22 In contrast, the FCRs for CETP at the end of ANA treatment were 0.18 and 0.25 pools/d, which are closer to the FCR of apoA-I observed in these participants (Table 3 ). There was a significant correlation between ANA-induced changes in apoA-I FCR and changes in CETP FCR (r=0.40; P=0.037).
Previous studies in CETP deficient participants identified apoA-I lipoproteins in the LDL density range. 23 We measured apoA-I levels in the LDL density range (1.019-1063 g/mL) during statin or PBO treatment and found that they were usually below the lower limit of the assay (<3 mg/dL) or, if present, were low (Table IV in the online-only Data Supplement). However, we did observe a greater number of participants with measureable or higher levels of apoA-I in this density range after ANA treatment.
Discussion
HDL is the most complex, heterogeneous, protein-enriched, and lipid-poor class of lipoproteins, varying in density (d=1.063-1.210 g/L), in diameter (7-13 nm), in the number of apoA-I per particle (2) (3) (4) , and in the presence or absence of other proteins and apolipoproteins. The study of HDL metabolism and functionality has been challenging because of dynamic nature of its lipid components, which can be catabolized or transferred between lipoproteins, and the rapid exchanges of its apolipoproteins between its subspecies and other lipoprotein classes. Studies conducted over the past 4 decades, with either exogenous or endogenous labeling of apoA-I, have demonstrated that, in general, low levels of apoA-I are associated with increased FCRs of the protein although some individuals with low apoA-I levels do have defects in the secretion of the protein into plasma. [24] [25] [26] The FCR of HDL apoA-I is affected mainly by size, density, and core lipid composition; larger, more buoyant HDL are cleared more slowly than smaller, denser HDL. [26] [27] [28] The physical-biochemical characteristics of HDL result from the actions of lipoprotein lipase, hepatic lipase, endothelial lipase, lecithin-cholesterol acyltransferase, and CETP. In this study, ANA treatment increased HDL-C dramatically in both groups while decreasing HDL-triglyceride. These changes were paralleled by dramatic shifts in the size distribution of HDL toward larger, α-1 particles and a significant decrease in the FCR of apoA-I. In accord with our results, individuals completely deficient in CETP have large, mainly α-1-sized, CE-enriched HDL with increased apoA-I levels and low apoA-I FCRs. [29] [30] [31] Our results in the PBO-ANA group are similar to those reported by Brousseau et al 16 for torcetrapib monotherapy. However, whereas Brousseau et al 16 did not observe a reduction in apoA-I FCR in participants taking both torcetrapib and ATV, we observed comparable effects of ANA on apoA-I FCR in participants receiving either PBO or statin as background treatment. Brousseau et al 16 found increased apoA-I PRs when torcetrapib was added to ATV; we saw no change in apoA-I PR in our study when comparing ATV alone with ATV plus ANA. The reasons for these differences are unclear; they may be related to differences between torcetrapib and ANA or may simply reflect the fact that the torcetrapib study was substantially smaller. As noted above, we found marked absolute and relative increases in apoA-I containing α-1 particles with, in general, decreases in apoA-I α-2, -3, and -4 subclasses. Brousseau et al 16 reported similar effects of torcetrapib on the distribution of apoA-I across HDL subpopulations, with increased apoA-I in the large α-1 subpopulation and decreases in the smaller α-3 subclass. These metabolic and compositional changes seem to be direct effects of CETP inhibition; ANA did not change the activities of hepatic lipase or lipoprotein lipase in PBO-ANA and ATV-ANA groups. 22 Additionally, the cholesterol esterification rate, which plays a key role in the maturation of HDL particles, fell by ≈30% during ANA therapy.
Importantly, the proportion of apoA-I particles in the pre-β range did not change during ANA treatment on either ATV or PBO background; in fact, the absolute level of preβ-1 apoA-I particles increased during ANA treatment. Pre-β apoA-I HDL particles are important acceptors of free cholesterol from cells via the ABCA1 transporter. 32 Our finding that the absolute amount of pre-β apoA-I-containing HDL is increased during ANA treatment is consistent with prior studies of ANA in hamsters 33 and supports the view that inhibition of CETP may increase cholesterol efflux capacity, as has been suggested. 34 The finding that ANA increased RCT in hamsters is consistent with this view. 35 The mechanisms by which CETP inhibition with ANA increases pre-β HDL remain to be established.
Previous studies of apoA-I metabolism during CETP inhibition have focused on apoA-I within HDL. 16 Ikewaki et al 29 isolated apoE-rich lipoproteins, containing apoA-I without apoB, from the d=1.019 to 1.063 g/mL fraction of plasma from patients with CETP deficiency; these apoE-rich lipoproteins were referred to as HDL1. Therefore, we determined if pharmacological inhibition of CETP affected the presence of apoA-I in the LDL density range. ANA-mediated inhibition of CETP significantly increased the number of individuals with measurable apoA-I within the isolated LDL density range fractions, both on the background of PBO and ATV treatment. It is likely that this apoA-I is on a large HDL1-like HDL particle. The relevance of large HDL1-like particles in human biology is currently unknown.
Although the apoA-II pool size increased significantly (but modestly) by 13% during ANA treatment (compared with the 31% increase in apoA-I pool size), we did not observe significant changes in either FCR or PR of apoA-II. Our results differ from those of Brousseau et al, 17 who observed a lowering of apoA-II FCR between 10% and 20% during torcetrapib therapy, dependent on the dose used. The reason for this difference in results is unclear although the participants studied by Brousseau et al 17 had much lower baseline HDL-C levels than our study subjects. We did observe a larger reduction of apoA-II FCR in the PBO-ANA group, but this was not statistically significant. The effects of CETP inhibition on apoA-II subpopulations were similar in the 2 studies, with a shift of apoA-II from small to larger α subclasses. It is notable that CETP inhibition has a substantially greater effect on apoA-I turnover and pool size than on apoA-II, which suggests that CETP inhibition may preferentially affect the LpA-I HDL particles that contain apoA-I but not apoA-II. Further studies are needed to explore this interesting implication.
For the first time, the effects of CETP inhibition on the kinetics of CETP were examined. The regulation of CETP gene expression and control of plasma CETP concentration by its synthesis have been well defined in animal models. 36, 37 Large cohort studies have identified noncoding genetic variants that affect plasma CETP levels 38 most likely through affecting transcription of the CETP gene. The impact of the synthesis and fractional clearance of CETP on its plasma concentrations has not been reported in humans. Our current findings indicate that treatment with a CETP inhibitor is associated with a marked increase in plasma levels of the protein because of a decrease in the FCR without a change in PR. Of note, the FCR of CETP was similar to that of LDL apoB during treatment with PBO or ATV alone. 22 This finding is not consistent with in vitro data where CETP was found mainly in the lipoproteinfree region of untreated plasma. 23 ANA forms a complex with CETP and HDL, 23 a model concordant with our finding that, during ANA treatment, the FCR for CETP was much closer to the FCR of apoA-I, and that changes in CETP FCR on ANA were strongly related to changes in apoA-I FCR. Validation of the model 23 will require further studies.
A limitation of this study is the fixed sequence protocol. Thus, although the study was double-blind regarding PBO plus ANA versus ATV plus ANA, it was single-blind regarding the administration of ANA, which the investigators knew during the second treatment period. Because of the extremely long half-life of ANA, a crossover design was not possible and a parallel arm study would have meant increasing the size of the study by 3-to 4-fold. A study effect or investigator-mediated bias cannot, therefore, be ruled out, but seems unlikely considering the magnitude of changes in plasma HDL-C and LDL-C levels. In conclusion, ANA, a CETP inhibitor, significantly increased plasma levels of HDL-C, apoA-I, and, to a lesser extent, apoA-II. The increase in apoA-I levels resulted from a significant reduction in the FCR of apoA-I without a change in PR; the increase in apoA-II, which was smaller, was not clearly associated with changes in either FCR or PR of the protein. Concomitant with the changes in plasma levels, there was a shift of HDL subclasses from smaller to larger species, but the absolute mass of both the pre-β1 and pre-β2 subclasses increased as well. CETP mass doubled during treatment with ANA and this change resulted from a significant reduction in the FCR of the protein with no change in synthesis. During the PBO period, the FCR of CETP was similar to that of LDL apoB; during ANA treatment, the FCR of CETP was similar to that of apoA-I, suggesting that CETP may be associated with HDL or apoA-I during treatment with ANA. These results enhance our understanding of the effects of potent CETP inhibition on HDL apolipoprotein kinetics and subclass distribution, and for the first time provide a clear explanation for the increase in plasma CETP mass with CETP inhibition. We must note, however, that our studies do not inform directly the issue of how CETP inhibitors effect RCT, which is determined by net efflux of cholesterol from peripheral tissues to the liver and then to the intestine for excretion. The fact that free-living individuals with increased HDL-C levels have reduced FCRs 26 and reduced risk for CVD supports the hypothesis that treatments to lower the FCR of apoA-I while raising HDL-C will be beneficial. We await the results of the REVEAL study, the last remaining clinical trial testing this hypothesis.
